HomeCompareORYZF vs PEP

ORYZF vs PEP: Dividend Comparison 2026

ORYZF yields 59.88% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORYZF wins by $505.8K in total portfolio value
10 years
ORYZF
ORYZF
● Live price
59.88%
Share price
$3.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$647.7K
Annual income
$151,154.17
Full ORYZF calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — ORYZF vs PEP

📍 ORYZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORYZFPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORYZF + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORYZF pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORYZF
Annual income on $10K today (after 15% tax)
$5,089.82/yr
After 10yr DRIP, annual income (after tax)
$128,481.04/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, ORYZF beats the other by $75,886.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORYZF + PEP for your $10,000?

ORYZF: 50%PEP: 50%
100% PEP50/50100% ORYZF
Portfolio after 10yr
$394.8K
Annual income
$106,514.93/yr
Blended yield
26.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

ORYZF
No analyst data
Altman Z
4.4
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORYZF buys
0
PEP buys
0
No recent congressional trades found for ORYZF or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORYZFPEP
Forward yield59.88%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$647.7K$141.9K
Annual income after 10y$151,154.17$61,875.67
Total dividends collected$536.9K$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ORYZF vs PEP ($10,000, DRIP)

YearORYZF PortfolioORYZF Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$16,688$5,988.02$10,849$509.42+$5.8KORYZF
2$27,195$9,339.09$11,969$750.47+$15.2KORYZF
3$43,323$14,223.60$13,500$1,124.14+$29.8KORYZF
4$67,531$21,176.11$15,680$1,721.66+$51.9KORYZF
5$103,108$30,849.85$18,929$2,715.34+$84.2KORYZF
6$154,347$44,020.82$24,023$4,450.80+$130.3KORYZF
7$226,736$61,585.45$32,510$7,669.92+$194.2KORYZF
8$327,159$84,550.92$47,709$14,093.60+$279.4KORYZF
9$464,078$114,017.62$77,415$28,083.48+$386.7KORYZF
10$647,717$151,154.17$141,922$61,875.67+$505.8KORYZF

ORYZF vs PEP: Complete Analysis 2026

ORYZFStock

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Full ORYZF Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this ORYZF vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORYZF vs SCHDORYZF vs JEPIORYZF vs OORYZF vs KOORYZF vs MAINORYZF vs MOORYZF vs PMORYZF vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.